Developments in purification methods for obtaining and evaluation of collagen derived endogenous angioinhibitors.
Collagen constitutes one of the vital components of the basement membrane scaffolds. Non-collagenous domains (NC1) derived from collagens exhibit potent anti-angiogenic properties, thus attaining significance in regulation of angiogenesis promoted diseases. Individual NC1 domains essential for anti-angiogenic evaluations are generally obtained through purification of individual non-collagenous domains, which have undergone steady developments for enhancing the yields, purpose of biological evaluations and solubility based on the nature of different NC1 domains. This review focuses on the method developments in obtaining biologically active NC1 domains and for specific evaluations in different scenarios.
['Gunda|Venugopal|V|', 'Verma|Raj K|RK|', 'Pawar|Smita C|SC|', 'Sudhakar|Yakkanti A|YA|']
D020533:Angiogenesis Inhibitors D001485:Basement Membrane D024141:Collagen Type IV D005109:Extracellular Matrix D005786:Gene Expression Regulation D006801:Humans D017434:Protein Structure, Tertiary
Non-collagenous domains (NC1) Anti-angiogenesis Different expression systems Different purification methods Extra cellular matrix (ECM) Type IV collagen